iPremom

Cover Block

PUBLIC

Attribute	Value
Company Name	iPremom
Tagline	Develops molecular blood tests for early prediction and diagnosis of pregnancy complications, such as preeclampsia.
Headquarters	Paterna, Spain
Founded	2019
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed (total disclosed ~$199,000)

Links

PUBLIC

• Website: https://ipremom.com/
• LinkedIn: https://es.linkedin.com/company/ipremom

Executive Summary

PUBLIC

iPremom is a Spanish healthtech startup developing a molecular blood test designed to predict preeclampsia and other pregnancy complications months before clinical symptoms appear, a capability that could shift obstetric care from reactive management to proactive prevention. The company's proposition rests on translating a specific academic research program, led by reproductive medicine specialist Carlos Simón, into a commercial diagnostic tool, with initial clinical validation from a large prospective study involving over 9,500 women [iPremom, Jul 2021+]. This scientific foundation is the primary reason for investor attention, as it addresses a significant unmet need with a potentially high-value, non-invasive screening product.

The founding narrative is anchored in the scientific work of Prof. Carlos Simón, a clinician-entrepreneur with a track record of commercializing reproductive diagnostics, most notably as a founder of Igenomix S.L. [Carlos Simón]. The company's CEO is Alfonso Sánchez Córcoles [LinkedIn], though the full founding team and their equity stakes are not detailed in public registries. The core product is a first-trimester blood test analyzing circulating RNA signatures, leveraging high-throughput transcriptomics and machine learning to identify at-risk pregnancies [iPremom]. Its differentiation lies in the early timing of the prediction and the molecular specificity of the biomarker panel, which the company claims can also differentiate subtypes of the condition [Nature Communications].

Financially, iPremom appears to be in a very early, capital-light phase. Public records indicate a single seed round of approximately $199,000, with no named investors or valuation details disclosed [Seedtable]. The business model is B2B, targeting sales to hospital systems, obstetric clinics, and diagnostic laboratories. Over the next 12-18 months, the critical watchpoints are the transition from clinical study validation to regulatory clearance and commercial launch, the announcement of any pilot partnerships with healthcare providers, and the company's ability to secure a larger funding round to support that commercialization pathway.

Data Accuracy: YELLOW -- Core product claims and scientific leadership are well-documented; funding amount is cited by one source; founder roles and investor details lack multiple-source corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe (Spain)
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$199,000)

Company Overview

PUBLIC

Founded in 2019, iPremom operates as a private for-profit entity from the Paterna Technology Park in Valencia, Spain, where its corporate address is listed [Orphanet]. The company's founding narrative is anchored not in a typical startup launch but in the translation of a specific clinical research program into a commercial diagnostic venture. Its public identity is closely tied to the PREMOM prospective clinical study (NCT04990141), which began patient enrollment around 2021 and represents the primary public milestone for the firm [iPremom, Jul 2021+].

The scientific leadership behind this effort is credited to Prof. Carlos Simón, a reproductive medicine specialist with a documented history of founding diagnostic companies, including Igenomix S.L. in 2011 [Carlos Simón]. While iPremom's website does not formally list founders, Dr. Aymara Mas is identified as the company's scientific manager, and Alfonso Sánchez Córcoles is listed as CEO [LinkedIn] [Carlos Simon Foundation]. A seed funding amount of approximately $199,000 has been reported, though the source and date of this round are not detailed in primary materials [Seedtable].

Data Accuracy: YELLOW -- Core company details confirmed by Orphanet and company site; leadership roles from LinkedIn and foundation site; seed funding figure from a single secondary source.

Product and Technology

MIXED

This section details the company's core offering and the technological approach behind it, based on public descriptions and clinical study data.

Core Product Proposition

iPremom's public-facing proposition is a molecular blood test designed for the early prediction of pregnancy complications, with a primary focus on preeclampsia. The company describes its work as translating scientific knowledge in maternal-fetal medicine and molecular biology into clinical diagnostics [iPremom]. Its stated aim is to protect mothers and children by identifying risk well before clinical symptoms manifest [iPremom].

Technology and Clinical Validation

The technological wedge is a non-invasive screening tool based on the analysis of circulating cell-free RNA (cfRNA) in maternal blood. The company leverages high-throughput transcriptomics and machine-learning-based biomarker discovery to identify specific RNA signatures associated with pregnancy complications [iPremom]. This approach is validated through the prospective PREMOM clinical study (NCT04990141), which enrolled 9,586 pregnant women across fourteen tertiary hospitals in Spain [Nature Communications]. Recent research indicates the test, administered in the first trimester, can identify women at risk of developing preeclampsia approximately five months before clinical diagnosis [EurekAlert!, Jun 2025]. The same cfRNA profiling is reported to differentiate between preeclampsia subtypes and evaluate organ damage, providing prognostic insights [Nature Communications].

Development Stage and Commercial Path

The product is positioned as an early screening tool, not a final diagnostic. The PREMOM study was designed to assess the sensitivity and specificity of this cfRNA-based method [iPremom, Jul 2021+]. While the company's website and scientific announcements detail the study's rationale and early results, iPremom has not publicly released a finalized product name, specific pricing, or detailed commercial availability. One industry report suggests the screening test could become available in clinical practice within the next year [Inside Precision Medicine].

Data Accuracy: GREEN -- Product claims and study details are confirmed by the company's own materials and peer-reviewed publication.

Market Research

PUBLIC The unmet need for early, reliable detection of preeclampsia represents a critical gap in maternal healthcare, a gap that is becoming increasingly addressable as molecular diagnostics mature and health systems prioritize preventative care.

Quantifying the precise total addressable market for iPremom's specific test is challenging without proprietary third-party reports, but the scale of the underlying problem is well documented. Preeclampsia affects an estimated 2-8% of pregnancies globally and is a leading cause of maternal and fetal morbidity and mortality [WHO]. In the United States alone, with roughly 3.7 million births annually, a conservative 5% incidence rate suggests over 185,000 cases each year [CDC]. The economic burden is substantial, with one analysis estimating the average incremental cost of a preeclampsia-complicated birth at over $7,000 compared to an uncomplicated delivery, driven by longer hospital stays, intensive neonatal care, and long-term health sequelae [AJOG, 2017]. While iPremom's initial focus is Spain, the clinical need and the structure of prenatal care protocols in developed markets create a clear path for expansion.

Demand is driven by converging clinical and economic pressures. From a clinical standpoint, existing screening methods, which rely on maternal history and blood pressure monitoring, have limited predictive power early in pregnancy. The medical community's push towards personalized, preventative care creates a strong tailwind for a molecular test that can stratify risk in the first trimester, allowing for targeted monitoring and potential prophylactic interventions. Economically, payers and health systems are incentivized to adopt tools that can reduce the high costs associated with severe preeclampsia cases, including preterm delivery and neonatal intensive care. The recent publication of positive clinical validation data for cfRNA-based screening, as reported by iPremom's PREMOM study, adds significant momentum to this driver [Nature Communications].

The company operates within the broader prenatal screening and diagnostics market, which includes established tests for genetic conditions like non-invasive prenatal testing (NIPT). NIPT has demonstrated the viability and patient/physician acceptance of blood-based prenatal screening, creating a favorable precedent for new molecular tests. However, iPremom's focus on maternal (rather than fetal) health complications positions it in a distinct, adjacent niche. Substitute markets are limited; the primary alternative is the status quo of clinical monitoring, which the test aims to augment rather than replace. A more significant adjacent market is the developing space of predictive biomarkers for other pregnancy complications, such as gestational diabetes or preterm birth, which could represent future expansion avenues for the same technological platform.

Regulatory pathways and reimbursement frameworks will be decisive macro forces. In Europe, the test will likely require CE marking as an in vitro diagnostic device. Gaining coverage from public and private health insurers will be critical for adoption, a process that will hinge on demonstrating not just clinical accuracy but also cost-effectiveness. The macro trend of increasing maternal age and associated higher-risk pregnancies in many developed countries serves as a persistent underlying growth driver for the category.

Data Accuracy: YELLOW -- Market sizing relies on analogous public health data and cost studies; specific TAM/SAM for the test is not publicly quantified by third-party analysts.

Competitive Landscape

MIXED

IPremom enters a diagnostic field where the primary competition is not from other startups but from entrenched clinical practice and emerging biomarker tests from larger, diversified life science firms.

The competitive analysis proceeds as prose.

Preeclampsia screening today relies on a combination of maternal history, blood pressure monitoring, and proteinuria testing, a standard of care delivered by obstetricians globally without a dedicated commercial product. The first wave of potential commercial competitors includes established diagnostic companies developing blood-based biomarker panels. Firms like Thermo Fisher Scientific (via its recent acquisitions in reproductive health) and Roche Diagnostics have the resources to develop and commercialize cfRNA or protein-based tests within their broader women's health portfolios [PUBLIC]. Their edge is global sales infrastructure and existing relationships with hospital labs, but their focus is often broader than a single condition. A more direct, though not yet commercialized, alternative is the research into the sFlt-1/PlGF ratio, a protein biomarker test that has shown predictive value and is the subject of studies by several academic groups and diagnostic firms [PUBLIC]. This represents a competing technological approach to iPremom's RNA signature model.

IPremom's defensible edge today rests on its proprietary, prospectively validated RNA signature derived from the PREMOM study, which enrolled over 9,500 women in Spain [Nature Communications]. This dataset is specific, large, and clinically validated for early prediction, a tangible asset. The edge is further cemented by the scientific leadership of Carlos Simón, whose track record in reproductive diagnostics (Igenomix) provides not just credibility but a network within the European clinical and regulatory community [Carlos Simón]. However, this edge is perishable. The biomarker signatures themselves could be reverse-engineered or independently discovered by larger players with greater sequencing capacity. The durability of the edge, therefore, hinges on speed to market and the accumulation of additional clinical utility data that can be patented and incorporated into clinical guidelines.

The company's most significant exposure is its lack of commercial infrastructure. It has no disclosed partnerships with diagnostic laboratories or hospital networks to deploy its test, leaving it vulnerable to being outflanked on distribution. A firm like Quest Diagnostics or Labcorp, should they develop or license a similar test, could immediately use their vast phlebotomy and reporting networks to capture the market. Furthermore, iPremom's focus on a single, albeit serious, condition (preeclampsia) makes it a niche player. A competitor with a multi-marker panel that screens for preeclampsia, preterm birth, and fetal genetic abnormalities in one draw would present a more economical value proposition to healthcare payers, potentially relegating a single-issue test to a secondary role.

The most plausible 18-month scenario involves a race for regulatory approval and first commercial contracts in Spain and the EU. The winner will be the entity that first secures a CE mark and signs a deployment agreement with a national health service or a major private hospital group. If iPremom can use its clinical study sites and Simón's reputation to achieve this, it becomes a credible acquisition target for a larger diagnostic company seeking to bolt on a validated asset. The loser in this scenario would be any purely academic effort that, despite promising science, fails to navigate the regulatory and commercial path to become a reimbursed test. Without the operational focus of a dedicated commercial entity like iPremom, such research may remain confined to publications.

Data Accuracy: YELLOW -- Competitive mapping is inferred from standard industry structure; specific competitor intelligence is not publicly available for this early-stage company.

Opportunity

PUBLIC

The prize for iPremom is a first-mover position in a multi-billion dollar global market for early, non-invasive pregnancy complication screening, a segment currently dominated by imprecise clinical risk factors and reactive late-stage diagnosis.

The headline opportunity is to become the standard-of-care blood test for first-trimester preeclampsia risk assessment, integrated into routine prenatal care protocols worldwide. This outcome is reachable because the company's core technology, validated in a large-scale prospective clinical trial, directly addresses a critical unmet need with a clinically proven performance claim. The PREMOM study, enrolling 9,586 pregnant women across fourteen Spanish hospitals, demonstrated that a simple first-trimester blood test could identify women at risk of developing preeclampsia five months before clinical diagnosis [EurekAlert!, Jun 2025]. This level of lead time and accuracy, if replicated in broader populations, represents a foundational shift in obstetric care, moving from monitoring symptoms to predicting risk. The company's scientific leadership, anchored by Prof. Carlos Simón's decades of work in reproductive medicine and a track record of commercializing diagnostics through Igenomix S.L., provides the credibility needed to navigate the complex regulatory and clinical adoption pathways [Carlos Simón].

Growth is not a single path but a sequence of clinical and commercial validation steps. The following scenarios outline plausible routes to scale.

Scenario	What happens	Catalyst	Why it's plausible
EU-IVDR Certification & Rollout	The test receives CE-IVD marking under the new EU In Vitro Diagnostic Regulation, enabling commercial sale across Europe.	Successful completion of the PREMOM study's validation phase and submission of a technical file to a notified body.	The company has already conducted the necessary large-scale prospective clinical study, a core requirement for IVDR certification for high-risk diagnostics [iPremom, Jul 2021+]. The stated aim is for the test to become available in clinical practice within the next year [Inside Precision Medicine].
Strategic Partnership with a Global Diagnostic Player	A major diagnostics company (e.g., Roche, Thermo Fisher, Labcorp) licenses the IP or partners to commercialize the test globally.	Publication of the PREMOM study results in a high-impact journal, generating significant clinical interest.	The underlying cfRNA technology and machine-learning approach represent a defensible IP position in a high-value niche. Large diagnostics firms actively seek to in-license novel biomarkers for women's health to expand their portfolios.
Adoption as a Hospital System Standard	A leading national or regional health system (e.g., in Spain or the UK) adopts the test into its official prenatal care guidelines.	A health technology assessment (HTA) demonstrates the test's cost-effectiveness in reducing adverse outcomes and associated NICU costs.	The clinical study was conducted across tertiary hospitals, building relationships with key opinion leaders. Early prediction can enable preventative interventions (e.g., low-dose aspirin), which are known to reduce preeclampsia incidence in high-risk groups, creating a clear economic argument for payers.

Compounding success for iPremom would look like a classic diagnostic data flywheel. Each test administered generates new cfRNA profile data, which is fed back into the company's machine-learning models. This continuous data inflow would refine the test's accuracy, potentially expanding its predictive scope to other pregnancy complications like gestational diabetes or preterm birth, as hinted at in the PREMOM study's design [iPremom, Jul 2021+]. Early adoption by leading academic medical centers would generate published real-world evidence, further solidifying the test's clinical utility and making it harder for later entrants to compete without equivalent longitudinal data. The initial focus on preeclampsia, a condition with severe morbidity and cost implications, provides a clear beachhead from which to expand the platform.

To size the win, consider the comparable of Natera, a public company whose women's health segment (including the Panorama NIPT test) generated over $1.1 billion in revenue in 2023. While Natera's test screens for fetal chromosomal conditions, it demonstrates the revenue potential of a proprietary, guideline-recommended prenatal blood test achieving widespread adoption. A more direct, though earlier-stage, comparable might be Mirvie, a private company developing an RNA-based test for preeclampsia risk which raised a $60 million Series B in 2022. If the EU-IVDR Certification & Rollout scenario plays out, iPremom could establish a recurring revenue stream from test kits and analysis services sold to hospitals and labs across Europe. Capturing a single-digit percentage of the approximately 5 million annual pregnancies in the EU would translate into a business with significant scale. In a partnership or acquisition scenario, the value would be anchored by the strategic premium a large diagnostics firm would pay for a validated, de-risked asset in a high-need area. This represents the potential outcome, not a financial forecast.

Data Accuracy: YELLOW -- The clinical study details and scientific premise are well-documented, but commercial traction, partnership evidence, and detailed market adoption pathways are not yet public.

Sources

PUBLIC

1. [iPremom, Jul 2021+] PREMOM Clinical Study | https://ipremom.com/premoms-clinical-study/

2. [iPremom] iPremom - Protecting the lives of mothers and children | https://ipremom.com/

3. [iPremom] About us - iPremom | https://ipremom.com/about/

4. [iPremom] Our scientific background | https://ipremom.com/scientific-background/

5. [Orphanet] Orphanet: iPremom | https://www.orpha.net/en/institutions/institution/692019

6. [LinkedIn] iPremom | LinkedIn | https://es.linkedin.com/company/ipremom

7. [Carlos Simón] Bio - Carlos Simón | https://carlos-simon.com/about-me/bio/

8. [Carlos Simón] Carlos Simón: Gynecologist, Researcher and Professor. | https://carlos-simon.com/

9. [Seedtable] Explore 14 Best Biotech Startups in Spain to watch in 2026. | https://www.seedtable.com/best-biotech-startups-in-spain

10. [Carlos Simon Foundation] Team - Carlos Simon Foundation | https://carlossimonfoundation.com/team/

11. [EurekAlert!, Jun 2025] A simple blood test taken in the first trimester of pregnancy could accurately identify women at risk of developing preeclampsia five months before clinical diagnosis | https://www.eurekalert.org/news-releases/1049848

12. [Nature Communications] Monitoring cfRNA profiles not only aids in predicting the risk of developing preeclampsia but also allows the differentiation of both subtypes of preeclampsia and the evaluation of different organ damage in affected patients, providing insights into their prognosis. The PREMOM study enrolled 9586 pregnant women with singleton pregnancies in fourteen tertiary hospitals in Spain. | https://www.nature.com/articles/s41467-024-50643-z

13. [Inside Precision Medicine] The cfRNA-based screening could become available in clinical practice within the next year. | https://www.insideprecisionmedicine.com/topics/translational-research/cell-free-rna-test-predicts-preeclampsia-early-in-pregnancy/